2020
DOI: 10.1097/md.0000000000021270
|View full text |Cite
|
Sign up to set email alerts
|

Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals

Abstract: In a hepatitis C virus (HCV)/HIV-positive Brazilian cohort, evaluate the safety and efficacy of HCV DAAs, the frequency of resistance substitutions in the HCV NS5A and NS5B genes and identify predictors of treatment failure. Retrospective multicenter study of HCV/HIV patients treated with sofosbuvir (SOF)-based regimens at 10 reference centers in Brazil. Clinical and virological data were collected. Genetic diversity in the NS5A and NS5B genes was assessed by direct nucleotide sequencing.… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
4
0
1

Year Published

2021
2021
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(7 citation statements)
references
References 56 publications
1
4
0
1
Order By: Relevance
“…Similar efficacy was documented in real-world studies of HCV/HIV coinfection conducted by Machado et [25][26][27][28][29]. In the abovementioned real-world analyses, patients were treated predominantly with genotype-specific regimens, only a few patients received the first available pangenotypic option of SOF ± DCV ± RBV.…”
Section: Discussionsupporting
confidence: 66%
“…Similar efficacy was documented in real-world studies of HCV/HIV coinfection conducted by Machado et [25][26][27][28][29]. In the abovementioned real-world analyses, patients were treated predominantly with genotype-specific regimens, only a few patients received the first available pangenotypic option of SOF ± DCV ± RBV.…”
Section: Discussionsupporting
confidence: 66%
“…A recent multicenter study of SOF/DCV from Brazil showed an SVR12 rate of 92.8% in an intention-to-treat analysis. There was no comparison with HCV mono-infected patients[ 344 ]. A similar SVR12 of 94% was reported in a retrospective study from the United States.…”
Section: Hcv/hiv Coinfectionmentioning
confidence: 99%
“…Only 3 cases in this study had received DAA before the diagnosis of HCC, all of which could achieve SVR. The safety and efficacy of DAA in HIV/HCV coinfection has recently been confirmed, so that DAA might contribute to the improvement of both HCV/ HCC treatment in this population, as has already been shown in Western countries (13,14). As mentioned above, the reason of small number in HCV treatment with DAA in Japan might be the reluctant to adopt it because of the possible insufficient collaboration between the hepatologists and hematologists, and/or HIV physicians.…”
Section: Discussionmentioning
confidence: 79%